CliffBio
biologic

Opdivo Qvantig

nivolumab and hyaluronidase-nvhy

Loss of exclusivityNovember 2037projected — 12-year biologic exclusivity estimate
CompanyBristol-Myers Squibb Company →See this company's full patent-cliff portfolio

Drug detail

Brand nameOpdivo Qvantig
Active ingredientnivolumab and hyaluronidase-nvhy
Strength300MG/2.5ML;5,000UNITS/2.5ML (120MG/2,000UNITS/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalNovember 2025
Marketing statusRx

More from Bristol-Myers Squibb Company

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.